AKTS · Insider Trading
Aktis Oncology, Inc. Common stock
Every open-market purchase and sale reported by AKTS officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-09-24 | Akos Czibere | Chief Medical Officer | MIXED | — | −$196.75K |
| 2026-07-21 | Ken Herrmann | Director | MIXED | — | −$116.42K |
| 2026-07-20 | Ken Herrmann | Director | MIXED | — | −$77.01K |
| 2026-07-10 | Shulamit Ron-Bigger | Chief Operating Officer | MIXED | — | −$1.20M |
| 2026-07-10 | Akos Czibere | Chief Medical Officer | MIXED | — | −$1.14M |
| 2026-04-16 | Glenn Gormley | Director | A | +37,866 deriv. | — |
| 2026-01-14 | MPM ASSET MANAGEMENT LLC | 10%+ Owner | MIXED | +29,755,065 | +$60.09M |
| 2026-01-14 | MPM ONCOLOGY INNOVATIONS FUND LP | 10%+ Owner | MIXED | +79,346,840 | +$160.24M |
| 2026-01-14 | Todd Foley | Director | MIXED | +4,235,403 | +$4.19M |
| 2026-01-12 | Lloyd Mitchell Segal | Director | C | +19,631 | — |
| 2026-01-12 | Helen Susan Kim | Director | MIXED | +5,829,212 | +$15.03M |
| 2026-01-12 | Oleg Nodelman | Director | MIXED | +9,648,938 | +$80.00M |
| 2026-01-12 | VIDA VENTURES II-A, LLC | 10%+ Owner | MIXED | +11,658,424 | +$30.06M |
| 2024-01-31 | Kenneth Boller | CFO | Buy | +60,000 | +$30.00K |
| 2024-01-31 | Jeffrey B. Shealy | Chief Executive Officer | Buy | +1,310,000 | +$655.00K |
| 2024-01-31 | Arthur Geiss | Director | Buy | +50,000 | +$25.00K |
| 2024-01-31 | David Aichele | EVP of Business Development | Buy | +80,000 | +$40.00K |
| 2023-12-20 | Kenneth Boller | CFO | Sell | −1,200 | −$865 |
| 2023-12-20 | David Aichele | EVP of Business Development | Sell | −1,500 | −$1.08K |
| 2023-11-22 | David Aichele | EVP of Business Development | Sell | −2,600 | −$1.53K |
| 2023-11-22 | Kenneth Boller | CFO | Sell | −1,700 | −$1.00K |
| 2023-11-08 | Steven Denbaars | Director | A | +38,250 | — |
| 2023-11-08 | Jerry D Neal | Director | A | +125,750 | — |
| 2023-11-08 | Jeffrey McMahon | Director | A | +78,250 | — |
| 2023-11-08 | Arthur Geiss | Director | A | +138,333 | — |
| 2023-11-08 | James Michael McGuire | Director | A | +83,500 | — |
| 2023-11-08 | Michelle Petock | Director | A | +185,000 deriv. | — |
| 2023-11-08 | Suzanne B Rudy | Director | A | +108,250 | — |
| 2023-09-28 | Jeffrey B. Shealy | Chief Executive Officer | A | +80,000 | — |
| 2023-09-15 | David Aichele | EVP of Business Development | A | +40,000 | — |
| 2023-09-15 | Kenneth Boller | CFO | A | +40,000 | — |
| 2023-09-13 | David Aichele | EVP of Business Development | Sell | −5,300 | −$5.78K |
| 2023-09-13 | Kenneth Boller | CFO | Sell | −3,900 | −$4.29K |
| 2023-08-22 | Steven Denbaars | Director | Sell | −7,000 | −$12.81K |
| 2023-03-23 | Michelle Petock | Director | A | +24,151 | — |
| 2023-03-10 | James Michael McGuire | Director | A | +2,002 | — |
| 2023-02-14 | Kenneth Boller | CFO | Sell | −800 | −$3.50K |
| 2023-01-25 | Steven Denbaars | Director | A | +18,182 | +$50.00K |
| 2023-01-24 | Jeffrey B. Shealy | Chief Executive Officer | A | +327,273 | +$900.00K |
| 2022-12-21 | David Aichele | EVP of Business Development | Sell | −1,480 | −$4.65K |
| 2022-12-21 | Jeffrey B. Shealy | Chief Executive Officer | Sell | −2,340 | −$6.65K |
| 2022-12-21 | Kenneth Boller | CFO | Sell | −1,200 | −$3.50K |
| 2022-12-08 | Steven Denbaars | Director | Sell | −7,000 | −$24.99K |
| 2022-11-28 | David Aichele | EVP of Business Development | Sell | −1,850 | −$6.51K |
| 2022-11-28 | Jeffrey B. Shealy | Chief Executive Officer | Sell | −1,950 | −$6.90K |
| 2022-11-28 | Kenneth Boller | CFO | Sell | −1,200 | −$4.22K |
| 2022-11-23 | David Aichele | EVP of Business Development | A | +35,000 | — |
| 2022-11-23 | Kenneth Boller | CFO | A | +25,000 | — |
| 2022-11-23 | Jeffrey B. Shealy | Chief Executive Officer | A | +50,000 | — |
| 2022-11-14 | Jerry D Neal | Director | A | +65,722 | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| MPM ASSET MANAGEMENT LLC | 10%+ Owner | 7,570,168 | $119.08M |
| Helen Susan Kim | Director | 4,859,370 | $76.44M |
| Todd Foley | Director | 4,002,533 | $62.96M |
| MPM ONCOLOGY INNOVATIONS FUND LP | 10%+ Owner | 1,655,971 | $26.05M |
| Oleg Nodelman | Director | 347,305 | $5.46M |
| VIDA VENTURES II-A, LLC | 10%+ Owner | 134,842 | $2.12M |
| Shulamit Ron-Bigger | Chief Operating Officer | 34,200 | $537.97K |
| Lloyd Mitchell Segal | Director | 19,631 | $308.80K |
| Ken Herrmann | Director | 4,856 | $76.38K |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the AKTS quote page; the site-wide leaderboard is on the insider transactions hub.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.